Facilitators and Barriers to Eptinezumab Administration in Thailand

Launched by CHULALONGKORN UNIVERSITY · Jun 14, 2025

Keywords

ClinConnect Summary

This study is looking at how people in Thailand who have migraines experience a new treatment called eptinezumab, which is given through an IV drip every three months to help prevent migraines. The researchers want to understand what makes it easier or harder for patients and healthcare workers to use this treatment. They also want to see if eptinezumab helps reduce the number of migraine days each month and improves patients’ quality of life over six months.

People eligible to join include adults diagnosed with migraine by headache specialists who have received eptinezumab at a hospital in Bangkok. Both patients who have used similar migraine medicines before and those who have not can participate. Healthcare providers who give the treatment at the same hospital can also join. Participants will be asked to take part in interviews and fill out questionnaires about their migraine symptoms and daily life at the start, 3 months, and 6 months after treatment. This study aims to improve migraine care in Thailand and help more people access effective treatments like eptinezumab.

Gender

ALL

Eligibility criteria

• • Target Population
• • Group 1: Patients who were diagnosed migraine with or without aura or chronic migraine and have received eptinezumab.
• • Group 2: Healthcare providers (e.g. doctor, outpatient nurse and daycare nurse) who are responsible for providing eptinezumab to the patients.
• • Inclusion Criteria Group 1: People with migraine with or without aura or chronic migraine Inclusion criteria Group 1A
• • 1. Age ≥ 18 years
• • 2. Diagnosed with migraine with or without aura or chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\*
• • 3. Have received eptinezumab infusion at the King Chulalongkorn Memorial Hospital (KCMH)
• • 4. Have received other CGRP mAbs prior to starting eptinezumab
• • 5. Able to communicate in Thai fluently
• • 6. Provide informed consent Group 1B
• • <!-- -->
• • 1. Age ≥ 18 years
• • 2. Diagnosed with migraine with or without aura or chronic migraine according to the ICHD-3\*
• • 3. Have received eptinezumab infusion at the KCMH
• • 4. Have NEVER received any CGRP mAbs prior to starting eptinezumab
• • 5. Able to communicate in Thai fluently
• • 6. Provide informed consent
• • \* The diagnosis will be established by consensus between two headache specialists. In case of a discrepancy, conflicts will be resolved through a final consensus agreement between the two specialists prior to enrollment.
• • Group 2: Healthcare providers Inclusion criteria
• • <!-- -->
• • 1. Age ≥ 18 years
• • 2. Currently working at KCMH
• • 3. Have been working at KCMH for more than 3 months
• • 4. Involved in providing care to patients attending the Headache Clinic
• • 5. Able to communicate in Thai fluently
• • 6. Provide informed consent
• • Exclusion Criteria Group 1: People with migraine with or without aura or chronic migraine
• • 1. Participants who cannot completely participate in an in-depth interview (IDI) and questionnaires, either in-person or online
• • 2. Participants with headache disorders other than migraine with or without aura or chronic migraine
• • 3. Alcohol or drug use that, in the opinion of the investigator, would interfere with completion of study procedures
• • 4. A known history of allergy to eptinezumab Group 2: Healthcare providers
• • <!-- -->
• • 1. Participants who cannot completely participate in an IDI, either in-person or online